| Year |
Citation |
Score |
| 2020 |
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, et al. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000999. PMID 32658627 DOI: 10.1200/Jco.20.00999 |
0.388 |
|
| 2020 |
Ha CS, LeBlanc M, Schöder H, Pinnix CC, Bartlett NL, Evens AM, Hsi ED, Rimsza L, Knopp MV, Zhang J, Leonard JP, Kahl BS, Li H, Smith S, Constine LS, et al. Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia & Lymphoma. 1-6. PMID 32452714 DOI: 10.1080/10428194.2020.1768388 |
0.349 |
|
| 2019 |
Dai JY, LeBlanc M. Case-only trees and random forests for exploring genotype-specific treatment effects in randomized clinical trials with dichotomous endpoints. Journal of the Royal Statistical Society. Series C, Applied Statistics. 68: 1371-1391. PMID 32489221 DOI: 10.1111/Rssc.12366 |
0.326 |
|
| 2019 |
Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Advances. 3: 3132-3135. PMID 31648328 DOI: 10.1182/Bloodadvances.2019000526 |
0.388 |
|
| 2019 |
Zhao YQ, LeBlanc ML. Designing precision medicine trials to yield greater population impact. Biometrics. PMID 31598964 DOI: 10.1111/Biom.13161 |
0.364 |
|
| 2019 |
Zhao YQ, Redman MW, LeBlanc ML. Quantifying treatment effects using the personalized chance of longer survival. Statistics in Medicine. PMID 31502297 DOI: 10.1002/Sim.8363 |
0.375 |
|
| 2019 |
Zhao YQ, Zeng D, Tangen CM, LeBlanc ML. Robustifying Trial-Derived Optimal Treatment Rules for A Target Population. Electronic Journal of Statistics. 13: 1717-1743. PMID 31440323 DOI: 10.1214/19-Ejs1540 |
0.323 |
|
| 2019 |
Unger JM, Blanke CD, LeBlanc ML, Barlow WE, Hershman DL. Patients enrolled in clinical trials with Medicaid or no insurance and overall survival benefits from new interventions. Journal of Clinical Oncology. 37: 119-119. DOI: 10.1200/Jco.2019.37.27_Suppl.119 |
0.398 |
|
| 2019 |
Unger JM, Nghiem VT, Hershman DL, Vaidya R, LeBlanc ML, Blanke CD. The impact of NCI-sponsored network group clinical trials on guideline care and new drug indications. Journal of Clinical Oncology. 37: 6604-6604. DOI: 10.1200/Jco.2019.37.15_Suppl.6604 |
0.314 |
|
| 2019 |
Unger JM, Vaidya R, Albain KS, LeBlanc ML, Minasian LM, Gotay C, Henry NL, Fisch MJ, Ramsey SD, Blanke CD, Lyman GH, Hershman DL. Sex differences in adverse event reporting in SWOG chemotherapy, biologic/immunotherapy, and targeted agent cancer clinical trials. Journal of Clinical Oncology. 37: 11588-11588. DOI: 10.1200/Jco.2019.37.15_Suppl.11588 |
0.302 |
|
| 2019 |
Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Leblanc ML, Song JY, Fisher RI, et al. PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001 Blood. 134: 349-349. DOI: 10.1182/Blood-2019-123871 |
0.318 |
|
| 2019 |
Burack R, Li H, Adlowitz DG, Spence JM, Leblanc ML, Rimsza LM, Braziel RM, Spier CM, Kaminski MS, Leonard JP, Fisher RI, Smith SM, Friedberg JW. Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016 Blood. 134: 2771-2771. DOI: 10.1182/Blood-2019-121632 |
0.341 |
|
| 2018 |
Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials. Cancer Epidemiology. 55: 117-122. PMID 29936140 DOI: 10.1016/J.Canep.2018.06.005 |
0.339 |
|
| 2018 |
Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW. Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica. PMID 29472351 DOI: 10.3324/Haematol.2017.175059 |
0.342 |
|
| 2018 |
Ha CS, Li H, Schoder H, Pinnix CC, Brem E, Bartlett NL, Evens AM, Hsi ED, Rimsza LM, Leonard JP, Kahl BS, Leblanc ML, Smith SM, Constine LS, Friedberg JW. Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis Blood. 132: 2927-2927. DOI: 10.1182/Blood-2018-99-113133 |
0.337 |
|
| 2018 |
Stephens DM, Li H, Schoder H, Straus DJ, Moskowitz CH, Leblanc ML, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr P, Knopp MV, Hsi ED, Leonard JP, Kahl BS, et al. Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach Blood. 132: 929-929. DOI: 10.1182/Blood-2018-99-113034 |
0.373 |
|
| 2018 |
Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Barr P, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma Blood. 132: 1593-1593. DOI: 10.1182/Blood-2018-99-112752 |
0.392 |
|
| 2018 |
Burack R, Li H, Spence JM, Adlowitz D, Rimsza LM, Braziel RM, Spier CM, Kaminski MS, Leonard JP, Fisher RI, Leblanc ML, Smith SM, Friedberg JW. Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016 Blood. 132: 919-919. DOI: 10.1182/Blood-2018-99-111399 |
0.318 |
|
| 2017 |
Smith EP, Li H, Friedberg JW, Constine LS, Rimsza LM, Cook JR, Laport GG, Popplewell LL, Holmberg LA, Smith SM, LeBlanc M, Forman SJ, Fisher RI, Stiff PJ. Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29289757 DOI: 10.1016/J.Bbmt.2017.12.798 |
0.398 |
|
| 2017 |
Dai JY, Liang CJ, LeBlanc M, Prentice RL, Janes H. Case-only approach to identifying markers predicting treatment effects on the relative risk scale. Biometrics. PMID 28960244 DOI: 10.1111/Biom.12789 |
0.324 |
|
| 2017 |
Unger JM, LeBlanc M, Blanke CD. The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population. Jama Oncology. PMID 28586789 DOI: 10.1001/Jamaoncol.2017.0762 |
0.317 |
|
| 2017 |
Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR. Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute. 109. PMID 28040733 DOI: 10.1093/Jnci/Djw263 |
0.406 |
|
| 2017 |
Unger JM, LeBlanc ML, Blanke CD. The impact of positive SWOG treatment trials on population survival. Journal of Clinical Oncology. 35: 6513-6513. DOI: 10.1200/Jco.2017.35.15_Suppl.6513 |
0.328 |
|
| 2017 |
Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM, Klein EA, LeBlanc ML, Blanke CD, Goodman PJ, Minasian LM, Hershman DL. The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials. Journal of Clinical Oncology. 35: 1541-1541. DOI: 10.1200/Jco.2017.35.15_Suppl.1541 |
0.357 |
|
| 2017 |
Stephens DM, Li H, Persky D, Park SI, Bartlett NL, Swinnen LJ, Casulo C, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Leblanc ML, Song JY, Fisher RI, et al. Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592) Blood. 130: 4122-4122. DOI: 10.1182/Blood.V130.Suppl_1.4122.4122 |
0.369 |
|
| 2017 |
Hsi ED, Li H, Nixon AB, Evens AM, Schoder H, Straus DJ, Bartlett NL, Sweetenham JW, Barr PM, Fanale MA, Cook JR, Kahl BS, Leonard JP, Smith SM, Leblanc ML, et al. Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study Blood. 130: 4033-4033. DOI: 10.1182/Blood.V130.Suppl_1.4033.4033 |
0.301 |
|
| 2017 |
Persky D, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Leblanc ML, Song JY, Fisher RI, et al. A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592) Blood. 130: 1553-1553. DOI: 10.1182/Blood.V130.Suppl_1.1553.1553 |
0.32 |
|
| 2017 |
Scott DW, Li H, Harvey Y, Chan F, Mottok A, Boyle M, Evens AM, Schoder H, Straus DJ, Bartlett NL, Sweetenham JW, Barr PM, Fanale MA, Hsi ED, Cook JR, ... ... Leblanc M, et al. The 23‐Gene Gene Expression‐Based Assay Does Not Predict Interim Pet Scan Results After Abvd In Advanced Stage Classical Hodgkin Lymphoma In The Us Intergroup S0816 Trial Hematological Oncology. 35: 92-93. DOI: 10.1002/Hon.2437_81 |
0.343 |
|
| 2016 |
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. British Journal of Haematology. PMID 27992063 DOI: 10.1111/bjh.14480 |
0.303 |
|
| 2016 |
Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL. Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27986655 DOI: 10.1158/1055-9965.Epi-15-1336 |
0.334 |
|
| 2016 |
Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27382104 DOI: 10.1200/Jco.2015.65.4582 |
0.388 |
|
| 2016 |
Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM. Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. British Journal of Haematology. PMID 27072903 DOI: 10.1111/Bjh.14100 |
0.349 |
|
| 2016 |
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, et al. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27069074 DOI: 10.1200/Jco.2015.63.1119 |
0.353 |
|
| 2016 |
Dazard JE, Choe M, LeBlanc M, Rao JS. Cross-validation and Peeling Strategies for Survival Bump Hunting using Recursive Peeling Methods. Statistical Analysis and Data Mining. 9: 12-42. PMID 27034730 DOI: 10.1002/Sam.11301 |
0.376 |
|
| 2016 |
Unger JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. Jama Oncology. PMID 26967260 DOI: 10.1001/Jamaoncol.2015.6487 |
0.368 |
|
| 2016 |
LeBlanc M, Tangen C. Surrogates for Survival or Other End Points in Oncology. Jama Oncology. 2: 263-4. PMID 26605695 DOI: 10.1001/Jamaoncol.2015.4711 |
0.326 |
|
| 2015 |
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1482-90. PMID 25823738 DOI: 10.1200/Jco.2014.57.5092 |
0.341 |
|
| 2015 |
Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. Journal of the National Cancer Institute. 107. PMID 25540245 DOI: 10.1093/Jnci/Dju412 |
0.368 |
|
| 2015 |
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 125: 236-41. PMID 25395425 DOI: 10.1182/Blood-2014-06-584623 |
0.361 |
|
| 2015 |
Greenlee H, Unger J, LeBlanc M, Hershman DL. Abstract A44: Association between BMI at treatment initiation and cancer survival across multiple SWOG trials Cancer Prevention Research. 8. DOI: 10.1158/1940-6215.Prev-14-A44 |
0.363 |
|
| 2014 |
Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, et al. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4210-7. PMID 25125258 DOI: 10.1158/1078-0432.Ccr-14-0521 |
0.346 |
|
| 2014 |
Philip PA, Chansky K, LeBlanc M, Rubinstein L, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4176-85. PMID 24914040 DOI: 10.1158/1078-0432.Ccr-13-2024 |
0.423 |
|
| 2014 |
Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, et al. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. American Journal of Hematology. 89: 639-45. PMID 24633940 DOI: 10.1002/Ajh.23709 |
0.32 |
|
| 2014 |
Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, Hershman DL. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. Journal of the National Cancer Institute. 106: dju002. PMID 24627276 DOI: 10.1093/Jnci/Dju002 |
0.393 |
|
| 2014 |
Barr PM, Li H, Spier CM, Mahadevan D, Friedberg JW, LeBlanc ML, Ul Haq M, Flowers C, Wagner-Johnston ND, Cheson BD, Horwitz SM, Miller TP, Fisher RI. U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). Journal of Clinical Oncology. 32: 8523-8523. DOI: 10.1200/Jco.2014.32.15_Suppl.8523 |
0.318 |
|
| 2014 |
Smith EP, Li H, Friedberg JW, Constine L, Rimsza LM, Laport GG, Popplewell LL, Maloney DG, Leblanc M, Forman SJ, Fisher RI, Stiff PJ. SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987) Blood. 124: 676-676. DOI: 10.1182/Blood.V124.21.676.676 |
0.374 |
|
| 2014 |
Puvvada SD, Stiff PJ, Leblanc M, Cook JR, Kahl B, Li H, Rimsza LM, Friedberg JW, Smith SM. MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704 Blood. 124: 1710-1710. DOI: 10.1182/Blood.V124.21.1710.1710 |
0.343 |
|
| 2013 |
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, ... ... LeBlanc M, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. The New England Journal of Medicine. 369: 1681-90. PMID 24171516 DOI: 10.1056/Nejmoa1301077 |
0.347 |
|
| 2013 |
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6624-32. PMID 24130072 DOI: 10.1158/1078-0432.Ccr-13-1120 |
0.414 |
|
| 2013 |
Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2646-56. PMID 23669424 DOI: 10.1158/1078-0432.Ccr-12-2939 |
0.347 |
|
| 2013 |
Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 1587-93. PMID 23504948 DOI: 10.1093/Annonc/Mdt070 |
0.352 |
|
| 2013 |
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 314-20. PMID 23233710 DOI: 10.1200/Jco.2012.42.4101 |
0.416 |
|
| 2013 |
Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer. 119: 371-9. PMID 22833464 DOI: 10.1002/Cncr.27733 |
0.369 |
|
| 2012 |
Dai JY, Kooperberg C, Leblanc M, Prentice RL. Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction. Biometrika. 99: 929-944. PMID 23843674 DOI: 10.1093/Biomet/Ass044 |
0.313 |
|
| 2012 |
Othus M, Barlogie B, Leblanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3731-6. PMID 22675175 DOI: 10.1158/1078-0432.Ccr-11-2859 |
0.344 |
|
| 2012 |
Schilsky RL, Doroshow JH, LeBlanc M, Conley BA. Development and Use of Integral Assays in Clinical Trials Clinical Cancer Research. 18: 1540-1546. PMID 22422406 DOI: 10.1158/1078-0432.Ccr-11-2202 |
0.338 |
|
| 2012 |
LeBlanc ML, Tangen CM. Choosing Phase II Endpoints and Designs: Evaluating the Possibilities Clinical Cancer Research. 18: 2130-2132. PMID 22407830 DOI: 10.1158/1078-0432.Ccr-12-0454 |
0.328 |
|
| 2012 |
Rudser KD, LeBlanc ML, Emerson SS. Distribution-free inference on contrasts of arbitrary summary measures of survival. Statistics in Medicine. 31: 1722-37. PMID 22362470 DOI: 10.1002/Sim.4505 |
0.34 |
|
| 2012 |
Press OW, Unger JM, LeBlanc ML, Rimsza LM, Friedberg JW, Czuczman MS, Kaminski MS, Braziel RM, Spier CM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. Journal of Clinical Oncology. 30: 8001-8001. DOI: 10.1200/Jco.2012.30.15_Suppl.8001 |
0.428 |
|
| 2012 |
Kelly JL, Salles G, Goldman BH, Fisher RI, Casasnovas O, Press OW, Maloney DG, Soubeyran P, Rimsza LM, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies. Blood. 120: 2712-2712. DOI: 10.1182/Blood.V120.21.2712.2712 |
0.356 |
|
| 2011 |
Stiff PJ, Unger JM, Cook J, Constine LS, Couban S, Shea TC, Winter JN, Miller TP, Tubbs RR, Marcellus DC, Friedberg JW, Barton K, Mills GM, LeBlanc ML, Rimsa L, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8001. PMID 28023022 DOI: 10.1200/Jco.2011.29.15_Suppl.8001 |
0.339 |
|
| 2011 |
Rimsza LM, Unger JM, Tome ME, LeBlanc ML. A strategy for full interrogation of prognostic gene expression patterns: exploring the biology of diffuse large B cell lymphoma. Plos One. 6. PMID 21829609 DOI: 10.1371/Journal.Pone.0022267 |
0.307 |
|
| 2011 |
Rubinstein L, Leblanc M, Smith MA. More randomization in phase II trials: necessary but not sufficient. Journal of the National Cancer Institute. 103: 1075-7. PMID 21709273 DOI: 10.1093/Jnci/Djr238 |
0.387 |
|
| 2011 |
Hoering A, LeBlanc M, Crowley JJ. Seamless Phase I/II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents Clinical Cancer Research. 17: 640-646. PMID 21135145 DOI: 10.1158/1078-0432.Ccr-10-1262 |
0.321 |
|
| 2010 |
Tardif HL, Yao S, Goldman BH, Spier CM, LeBlanc ML, Rimsza LM, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM. Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas Blood. 116: 321-321. DOI: 10.1182/Blood.V116.21.321.321 |
0.324 |
|
| 2009 |
Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Archives of Otolaryngology--Head & Neck Surgery. 135: 869-74. PMID 19770418 DOI: 10.1001/Archoto.2009.122 |
0.301 |
|
| 2009 |
LeBlanc M, Rankin C, Crowley J. Multiple Histology Phase II Trials Clinical Cancer Research. 15: 4256-4262. PMID 19549777 DOI: 10.1158/1078-0432.Ccr-08-2069 |
0.364 |
|
| 2009 |
Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Randomized phase II designs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1883-90. PMID 19276275 DOI: 10.1158/1078-0432.Ccr-08-2031 |
0.35 |
|
| 2009 |
Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 114-9. PMID 19047289 DOI: 10.1200/Jco.2008.16.8021 |
0.343 |
|
| 2008 |
Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood. 112: 3425-33. PMID 18544678 DOI: 10.1182/Blood-2008-02-137372 |
0.357 |
|
| 2008 |
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2258-63. PMID 18413640 DOI: 10.1200/Jco.2007.13.6929 |
0.363 |
|
| 2008 |
Goldman B, LeBlanc M, Crowley J. Interim futility analysis with intermediate endpoints. Clinical Trials. 5: 14-22. PMID 18283075 DOI: 10.1177/1740774507086648 |
0.414 |
|
| 2008 |
Miller TP, Unger JM, Spier C, Stea B, Press OW, Friedberg JW, LeBlanc M, Fisher RI. Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313) Blood. 112: 3598-3598. DOI: 10.1182/Blood.V112.11.3598.3598 |
0.397 |
|
| 2007 |
Agrawal A, Moon J, Davis RK, Sakr WA, Giri SPG, Valentino J, LeBlanc M, Truelson JM, Yoo GH, Ensley JF, Schuller DE. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: Report of southwest oncology group phase 2 trial S9709 Archives of Otolaryngology-Head & Neck Surgery. 133: 1044-1050. PMID 17938330 DOI: 10.1001/Archotol.133.10.1044 |
0.361 |
|
| 2007 |
Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Laboratory Investigation; a Journal of Technical Methods and Pathology. 87: 979-97. PMID 17700562 DOI: 10.1038/Labinvest.3700665 |
0.316 |
|
| 2007 |
Rimsza LM, LeBlanc ML, Roberts RA, Unger JM, Miller TP, Sabalos CM, Martel RR, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues. Blood. 110: 50-50. DOI: 10.1182/Blood.V110.11.50.50 |
0.309 |
|
| 2007 |
Sweetenham JW, Hsi E, Goldman B, LeBlanc M, Tubbs RR, Cook JR, Press OW, Fisher RI, Rimsza LM. Numbers of Lymphoma Associated Macrophages (LAMS) and Regulatory T-Cells (Tregs) in Follicular Lymphoma (FL) Patients (pts) Treated with and without Monoclonal Antibody (MoAb)-Containing Therapy Do Not Correlate with Overall Survival (OS): A Study from the Southwest Oncology Group (SWOG). Blood. 110: 2602-2602. DOI: 10.1182/Blood.V110.11.2602.2602 |
0.356 |
|
| 2006 |
Fan J, Su XG, Levine RA, Nunn ME, Leblanc M. Trees for correlated survival data by goodness of split, with applications to tooth prognosis Journal of the American Statistical Association. 101: 959-967. DOI: 10.1198/016214506000000438 |
0.362 |
|
| 2005 |
Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8447-52. PMID 16230674 DOI: 10.1200/Jco.2005.03.1674 |
0.356 |
|
| 2005 |
LeBlanc M, Moon J, Crowley J. Adaptive risk group refinement. Biometrics. 61: 370-378. PMID 16011683 DOI: 10.1111/J.1541-0420.2005.020738.X |
0.343 |
|
| 2005 |
Urba SG, Moon J, Giri PGS, Adelstein DJ, Hanna EY, Yoo GH, LeBlanc M, Ensley JF, Schuller DE. Organ Preservation for Advanced Resectable Cancer of the Base of Tongue and Hypopharynx: A Southwest Oncology Group Trial Journal of Clinical Oncology. 23: 88-95. PMID 15625363 DOI: 10.1200/Jco.2005.04.017 |
0.368 |
|
| 2005 |
Press OW, Unger J, Maloney D, Braziel RM, LeBlanc M, Grogan T, Miller TP, Fisher RI. An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911. Blood. 106: 352-352. DOI: 10.1182/Blood.V106.11.352.352 |
0.388 |
|
| 2004 |
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. The New England Journal of Medicine. 351: 2159-69. PMID 15548776 DOI: 10.1056/Nejmoa041869 |
0.33 |
|
| 2004 |
Dave SS, Wright G, Tan B, Rosenwald A, Chan WC, Greiner TC, Weisenburger DD, Lynch JC, Vose JM, Armitage JO, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, ... LeBlanc M, et al. Lymphdx: A Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma. Blood. 104: 701-701. DOI: 10.1182/Blood.V104.11.701.701 |
0.337 |
|
| 2004 |
Crowley JJ, McCoy J, LeBlanc M, Barlogie B. Extreme Regression: A Statistical Technique for Finding Good or Poor Prognostic Groups, Illustrated Using Myeloma Patient Data from Intergroup Trial S9321. Blood. 104: 5202-5202. DOI: 10.1182/Blood.V104.11.5202.5202 |
0.416 |
|
| 2004 |
Spier CM, LeBlanc M, Chase EM, Fisher RI, Miller TP. Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736. Blood. 104: 3263-3263. DOI: 10.1182/Blood.V104.11.3263.3263 |
0.398 |
|
| 2004 |
Miller TP, Unger JM, Spier C, Stea B, Cantu E, LeBlanc M, Fisher RI. Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014). Blood. 104: 158-158. DOI: 10.1182/Blood.V104.11.158.158 |
0.413 |
|
| 2003 |
Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, ... ... LeBlanc M, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. The Journal of Experimental Medicine. 198: 851-62. PMID 12975453 DOI: 10.1084/Jem.20031074 |
0.343 |
|
| 2003 |
Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2466-73. PMID 12829664 DOI: 10.1200/Jco.2003.06.137 |
0.389 |
|
| 2003 |
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. 102: 1606-12. PMID 12738671 DOI: 10.1182/Blood-2003-01-0287 |
0.305 |
|
| 2003 |
Pauler DK, Hardin J, Faulkner JR, LeBlanc M, Crowley JJ. Survival Analysis with Gene Expression Arrays Handbook of Statistics. 23: 675-688. DOI: 10.1016/S0169-7161(03)23037-6 |
0.33 |
|
| 2002 |
LeBlanc M, Jacobson J, Crowley J. Partitioning and peeling for constructing prognostic groups. Statistical Methods in Medical Research. 11: 247-274. PMID 12094758 DOI: 10.1191/0962280202Sm286Ra |
0.334 |
|
| 1999 |
LeBlanc M, Crowley J. Adaptive regression splines in the Cox model. Biometrics. 55: 204-213. PMID 11318156 DOI: 10.1111/J.0006-341X.1999.00204.X |
0.34 |
|
| 1999 |
LeBlanc M, Crowley J. Using the bootstrap for estimation in group sequential designs: an application to a clinical trial for nasopharyngeal cancer. Statistics in Medicine. 18: 2635-2644. PMID 10495461 DOI: 10.1002/(Sici)1097-0258(19991015)18:19<2635::Aid-Sim200>3.0.Co;2-7 |
0.356 |
|
| 1999 |
Liu PY, Leblanc M, Desai M. False positive rates of randomized phase II designs Controlled Clinical Trials. 20: 343-352. PMID 10440561 DOI: 10.1016/S0197-2456(99)00009-4 |
0.335 |
|
| 1998 |
Wirth A, Prince HM, Wolf M, Machida U, Kami M, Hirai H, Mounier N, Gisselbrecht C, Lepage E, Kosmas C, Malamos NA, Antonopoulos MJ, Decaudin D, Miller TP, LeBlanc M, et al. Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma [1] (multiple letters) The New England Journal of Medicine. 339: 1475-1477. PMID 9841317 DOI: 10.1056/Nejm199811123392012 |
0.305 |
|
| 1998 |
Al-Sarraf M, LeBlanc M, Giri PGS, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099 Journal of Clinical Oncology. 16: 1310-1317. PMID 9552031 DOI: 10.1200/Jco.1998.16.4.1310 |
0.399 |
|
| 1998 |
Press OW, LeBlanc M, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP, Fisher RI. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 574-8. PMID 9469343 DOI: 10.1200/Jco.1998.16.2.574 |
0.399 |
|
| 1998 |
Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. Journal of Clinical Oncology. 16: 48-55. PMID 9440722 DOI: 10.1200/Jco.1998.16.1.48 |
0.362 |
|
| 1997 |
Miller TP, LeBlanc M, Grogan TM, Fisher RI, Graff JC. Follicular lymphomas: Do histologic subtypes predict outcome? Hematology/Oncology Clinics of North America. 11: 893-900. PMID 9336720 DOI: 10.1016/S0889-8588(05)70468-8 |
0.364 |
|
| 1996 |
Giri PG, LeBlanc M, Al-Sarraf M, Fu KK, Cooper J, Vuong T, Forastiere A, Adams G, Sakr W, Schuller D, Ensley J. 8 Improved survival with chemotherapy and radiation therapy versus radiation therapy alone in advanced nasopharyngeal cancer. Preliminary results of an intergroup randomized trial. Int 0099, SWOG 8892, RTOG 8817, ECOG 2388 International Journal of Radiation Oncology Biology Physics. 36: 162. DOI: 10.1016/S0360-3016(97)85348-5 |
0.316 |
|
| 1995 |
Leblanc M, Crowley J. Semiparametric Regression Functionals Journal of the American Statistical Association. 90: 95-105. DOI: 10.1080/01621459.1995.10476492 |
0.313 |
|
| 1993 |
Leblanc M, Crowley J. Survival Trees by Goodness of Split Journal of the American Statistical Association. 88: 457-467. DOI: 10.1080/01621459.1993.10476296 |
0.32 |
|
| 1990 |
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1563-74. PMID 2167954 DOI: 10.1200/Jco.1990.8.9.1563 |
0.407 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2017 |
Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM, Friedberg JW. A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. American Journal of Hematology. PMID 29266344 DOI: 10.1002/ajh.25010 |
0.3 |
|
| 2009 |
Dai JY, LeBlanc M, Kooperberg C. Semiparametric estimation exploiting covariate independence in two-phase randomized trials. Biometrics. 65: 178-87. PMID 18479485 DOI: 10.1111/J.1541-0420.2008.01046.X |
0.299 |
|
| 2014 |
Cook JR, Goldman B, Tubbs RR, Rimsza L, Leblanc M, Stiff P, Fisher R. Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. The American Journal of Surgical Pathology. 38: 494-501. PMID 24625415 DOI: 10.1097/Pas.0000000000000147 |
0.299 |
|
| 2013 |
Hoering A, Mitchell A, LeBlanc M, Crowley J. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents Clinical Trials. 10: 422-429. PMID 23529697 DOI: 10.1177/1740774513480961 |
0.299 |
|
| 1992 |
LeBlanc M, Crowley J. Relative risk trees for censored survival data. Biometrics. 48: 411-425. DOI: 10.2307/2532300 |
0.299 |
|
| 2017 |
Pashova H, LeBlanc M, Kooperberg C. Structured detection of interactions with the directed lasso. Statistics in Biosciences. 9: 676-691. PMID 29292402 DOI: 10.1007/S12561-016-9184-6 |
0.298 |
|
| 2005 |
Unger JM, Thompson IM, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer. 103: 1375-80. PMID 15739207 DOI: 10.1002/Cncr.20919 |
0.296 |
|
| 2020 |
Unger JM, Blanke CD, LeBlanc M, Barlow WE, Vaidya R, Ramsey SD, Hershman DL. Association of Patient Demographic Characteristics and Insurance Status With Survival in Cancer Randomized Clinical Trials With Positive Findings. Jama Network Open. 3: e203842. PMID 32352530 DOI: 10.1001/jamanetworkopen.2020.3842 |
0.294 |
|
| 2009 |
LeBlanc M, Kooperberg C. Adaptively weighted association statistics. Genetic Epidemiology. 33: 442-452. PMID 19170133 DOI: 10.1002/Gepi.20397 |
0.294 |
|
| 2015 |
Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood. 125: 992-8. PMID 25422100 DOI: 10.1182/Blood-2014-06-583369 |
0.294 |
|
| 2010 |
Sweetenham JW, Goldman B, LeBlanc ML, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Rimsza LM, Braziel RM, Hsi ED. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 1196-202. PMID 19875761 DOI: 10.1093/Annonc/Mdp460 |
0.293 |
|
| 2010 |
LeBlanc M, Kooperberg C. Boosting predictions of treatment success Proceedings of the National Academy of Sciences of the United States of America. 107: 13559-13560. PMID 20656935 DOI: 10.1073/Pnas.1008052107 |
0.292 |
|
| 2003 |
LeBlanc M, Kooperberg C, Grogan TM, Miller TP. Directed indices for exploring gene expression data. Bioinformatics (Oxford, England). 19: 686-93. PMID 12691980 DOI: 10.1093/Bioinformatics/Btg079 |
0.29 |
|
| 2018 |
Dai J, LeBlanc ML, Goodman PJ, Lucia MS, Thompson IM, Catherine T. Case-only analyses for identifying genotypes that modify the effect of finasteride in the Prostate Cancer Prevention Trial (PCPT): SWOG S9217. Journal of Clinical Oncology. 36: 1551-1551. DOI: 10.1200/Jco.2018.36.15_Suppl.1551 |
0.29 |
|
| 2012 |
Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 120: 1210-7. PMID 22734071 DOI: 10.1182/Blood-2012-04-423079 |
0.29 |
|
| 2020 |
Rutherford SC, Yin J, Pederson L, LaPlant B, Shadman M, Li H, LeBlanc ML, Blum KA, Dockter T, Martin P, Jung S, Grant BW, Rosenbaum CA, Ujjani CS, Barr PM, et al. Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials. Journal of Clinical Oncology. 38: 8038-8038. DOI: 10.1200/Jco.2020.38.15_Suppl.8038 |
0.289 |
|
| 2021 |
Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, Laubach C, LeBlanc M, Friedberg JW, Smith SM. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. Journal of Geriatric Oncology. PMID 34686472 DOI: 10.1016/j.jgo.2021.10.003 |
0.289 |
|
| 2001 |
Kooperberg C, Ruczinski I, Leblanc ML, Hsu L. Sequence analysis using logic regression Genetic Epidemiology. 21. PMID 11793751 DOI: 10.1002/Gepi.2001.21.S1.S626 |
0.287 |
|
| 2018 |
Dai JY, LeBlanc M, Goodman PJ, Lucia MS, Thompson IM, Tangen CM. Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride. Cancer Prevention Research (Philadelphia, Pa.). PMID 30538099 DOI: 10.1158/1940-6207.Capr-18-0284 |
0.285 |
|
| 2020 |
Dai JY, Stanford JL, LeBlanc M. A Multiple-Testing Procedure for High-Dimensional Mediation Hypotheses Journal of the American Statistical Association. 1-16. DOI: 10.1080/01621459.2020.1765785 |
0.283 |
|
| 2002 |
Abdolell M, LeBlanc M, Stephens D, Harrison RV. Binary partitioning for continuous longitudinal data: categorizing a prognostic variable. Statistics in Medicine. 21: 3395-409. PMID 12407680 DOI: 10.1002/Sim.1266 |
0.283 |
|
| 2002 |
Kooperberg C, Sipione S, LeBlanc M, Strand AD, Cattaneo E, Olson JM. Evaluating test statistics to select interesting genes in microarray experiments. Human Molecular Genetics. 11: 2223-32. PMID 12217950 DOI: 10.1093/Hmg/11.19.2223 |
0.283 |
|
| 2020 |
Redman MW, Papadimitrakopoulou V, Minichiello K, Gandara DR, Hirsch FR, Mack PC, Schwartz LH, Vokes EE, Ramalingam SS, Leighl NB, Bradley J, LeBlanc ML, Malik S, Miller VA, Sigal EV, et al. Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). Journal of Clinical Oncology. 38: 9576-9576. DOI: 10.1200/Jco.2020.38.15_Suppl.9576 |
0.28 |
|
| 2013 |
Pashova H, Leblanc M, Kooperberg C. Boosting for detection of gene-environment interactions Statistics in Medicine. 32: 255-266. PMID 22764060 DOI: 10.1002/Sim.5444 |
0.28 |
|
| 2015 |
Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, et al. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1514-24. PMID 25680375 DOI: 10.1158/1078-0432.Ccr-13-3473 |
0.28 |
|
| 2010 |
Kooperberg C, LeBlanc M, Obenchain V. Risk prediction using genome‐wide association studies Genetic Epidemiology. 34: 643-652. PMID 20842684 DOI: 10.1002/Gepi.20509 |
0.28 |
|
| 2008 |
Kooperberg C, LeBlanc M. Increasing the power of identifying gene × gene interactions in genome-wide association studies Genetic Epidemiology. 32: 255-263. PMID 18200600 DOI: 10.1002/Gepi.20300 |
0.279 |
|
| 2015 |
Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. British Journal of Haematology. PMID 26492567 DOI: 10.1111/bjh.13818 |
0.278 |
|
| 2004 |
Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, Bolwell BJ, Fisher RI. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 9: 529-39. PMID 12931122 DOI: 10.1016/S1083-8791(03)00205-2 |
0.276 |
|
| 2006 |
Dai JY, Ruczinski I, LeBlanc M, Kooperberg C. Imputation methods to improve inference in SNP association studies. Genetic Epidemiology. 30: 690-702. PMID 16986162 DOI: 10.1002/Gepi.20180 |
0.275 |
|
| 1995 |
Leblanc M, Crowley J. Step‐function covariate effects in the proportional‐hazards model Canadian Journal of Statistics-Revue Canadienne De Statistique. 23: 109-129. DOI: 10.2307/3315439 |
0.275 |
|
| 2021 |
Zhang S, LeBlanc ML, Zhao YQ. Restricted survival benefit with right-censored data. Biometrical Journal. Biometrische Zeitschrift. PMID 34970772 DOI: 10.1002/bimj.202000392 |
0.274 |
|
| 2001 |
Faraggi D, LeBlanc M, Crowley J. Understanding neural networks using regression trees: an application to multiple myeloma survival data. Statistics in Medicine. 20: 2965-76. PMID 11568952 DOI: 10.1002/Sim.912 |
0.272 |
|
| 1995 |
Tammemagi MC, Frank JW, Leblanc M, Artsob H, Streiner DL. Methodological issues in assessing reproducibility--a comparative study of various indices of reproducibility applied to repeat ELISA serologic tests for Lyme disease. Journal of Clinical Epidemiology. 48: 1123-1132. PMID 7636514 DOI: 10.1016/0895-4356(94)00243-J |
0.269 |
|
| 2013 |
Mehta S, Moon J, Hashmi M, Leblanc M, Huang CH, Rinehart E, Wolf GT, Urba SG, Banerjee SK, Williamson S. Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420. Oncology Reports. 29: 2095-100. PMID 23563900 DOI: 10.3892/or.2013.2374 |
0.268 |
|
| 2018 |
Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, et al. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017745083. PMID 29356608 DOI: 10.1200/JCO.2017.74.5083 |
0.266 |
|
| 2017 |
Kerr KF, LeBlanc M, Janes H. Comparisons of cancer staging systems should be based on overall performance in the population. Clinical Trials (London, England). 1740774517722141. PMID 28819997 DOI: 10.1177/1740774517722141 |
0.266 |
|
| 1996 |
Leblanc M, Tibshirani R. Combining Estimates in Regression and Classification Journal of the American Statistical Association. 91: 1641-1650. DOI: 10.1080/01621459.1996.10476733 |
0.265 |
|
| 2022 |
Rutherford SC, Yin J, Pederson L, Perez Burbano G, LaPlant B, Shadman M, Li H, LeBlanc ML, Kenkre VP, Hong F, Blum KA, Dockter T, Martin P, Jung SH, Grant B, et al. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102301. PMID 35787017 DOI: 10.1200/JCO.21.02301 |
0.264 |
|
| 2009 |
Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leukemia & Lymphoma. 50: 728-35. PMID 19373598 DOI: 10.1080/10428190902856808 |
0.264 |
|
| 2004 |
Ruczinski I, Kooperberg C, LeBlanc ML. Exploring interactions in high-dimensional genomic data: An overview of Logic Regression, with applications Journal of Multivariate Analysis. 90: 178-195. DOI: 10.1016/J.Jmva.2004.02.010 |
0.263 |
|
| 2006 |
Agrawal A, Moon J, Davis RK, Sakr WA, Giri S, Valentino J, LeBlanc M, Truelson JM, Ensley JF, Schuller DE. S105 Phase 2 Trial of CO2 Laser Supraglottic Laryngectomy and Irradiation: Experience of the Southwest Oncology Group Archives of Otolaryngology-Head & Neck Surgery. 132: 862-862. DOI: 10.1001/Archotol.132.8.862-A |
0.262 |
|
| 2009 |
Kooperberg C, Leblanc M, Dai JY, Rajapakse I. Structures and Assumptions: Strategies to Harness Gene × Gene and Gene × Environment Interactions in GWAS. Statistical Science : a Review Journal of the Institute of Mathematical Statistics. 24: 472-488. PMID 20640184 DOI: 10.1214/09-Sts287 |
0.262 |
|
| 1992 |
Tibshirani R, LeBlanc M. A Strategy for Binary Description and Classification Journal of Computational and Graphical Statistics. 1: 3-20. DOI: 10.1080/10618600.1992.10474573 |
0.259 |
|
| 2006 |
Adelstein DJ, Leblanc M. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2624-8. PMID 16763275 DOI: 10.1200/JCO.2005.05.3629 |
0.258 |
|
| 2004 |
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, ... ... LeBlanc M, et al. Follicular lymphoma international prognostic index. Blood. 104: 1258-65. PMID 15126323 DOI: 10.1182/Blood-2003-12-4434 |
0.257 |
|
| 2009 |
Dai JY, Leblanc M, Smith NL, Psaty B, Kooperberg C. SHARE: an adaptive algorithm to select the most informative set of SNPs for candidate genetic association. Biostatistics (Oxford, England). 10: 680-93. PMID 19605740 DOI: 10.1093/Biostatistics/Kxp023 |
0.256 |
|
| 2006 |
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4143-9. PMID 16896003 DOI: 10.1200/JCO.2006.05.8198 |
0.254 |
|
| 2020 |
Castellino SM, LeBlanc ML, Herrera AF, Parsons SK, Punnett A, Hodgson DC, Rutherford SC, Khan N, Constine LS, Davison K, Prica AA, Friedberg JW, Kelly KM. An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps8067 |
0.254 |
|
| 2012 |
Mittlböck M, Edler L, LeBlanc M, Niland J, Zwinderman K. Editorial: Second Issue for Computational Statistics for Clinical Research Computational Statistics & Data Analysis. 56: 995-997. DOI: 10.1016/J.Csda.2012.01.007 |
0.254 |
|
| 2012 |
Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman SD, Ditzler S, Pullar B, Robison K, White KF, Tunkey C, LeBlanc M, Randolph-Habecker J, Knoblaugh SE, Hansen S, Richards A, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proceedings of the National Academy of Sciences of the United States of America. 109: 7859-64. PMID 22550175 DOI: 10.1073/Pnas.1114718109 |
0.253 |
|
| 2004 |
Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, Krohn K. FDG-PET prediction of head and neck squamous cell cancer outcomes. Archives of Otolaryngology--Head & Neck Surgery. 130: 1361-7. PMID 15611393 DOI: 10.1001/Archotol.130.12.1361 |
0.251 |
|
| 1995 |
Tammemagi MC, Frank JW, LeBlanc M, Artsob H. Intra- and interlaboratory reproducibility of an ELISA serological test for Lyme disease. Canadian Journal of Infectious Diseases & Medical Microbiology. 6: 90-95. PMID 22416209 DOI: 10.1155/1995/626945 |
0.251 |
|
| 1995 |
LeBlanc M, Crowley J. A review of tree-based prognostic models Cancer Treatment and Research. 75: 113-124. PMID 7640160 DOI: 10.1007/978-1-4615-2009-2_6 |
0.25 |
|
| 1997 |
LeBlanc M. Restricted polynomial regression Computational Statistics & Data Analysis. 24: 153-167. DOI: 10.1016/S0167-9473(96)00059-X |
0.248 |
|
| 1998 |
LeBlanc M, Tibshirani R. Monotone Shrinkage of Trees Journal of Computational and Graphical Statistics. 7: 417-433. DOI: 10.1080/10618600.1998.10474786 |
0.248 |
|
| 2004 |
Nason M, Emerson S, LeBlanc M. CARTscans: A Tool for Visualizing Complex Models Journal of Computational and Graphical Statistics. 13: 807-825. DOI: 10.1198/106186004X11417 |
0.247 |
|
| 1998 |
LeBlanc M. Resampled quantile functions for error estimation and a relationship to density estimation Computational Statistics & Data Analysis. 29: 163-176. DOI: 10.1016/S0167-9473(98)00071-1 |
0.244 |
|
| 1995 |
Strathdee SA, Frank JW, McLaughlin J, Leblanc M, Major C, O'Shaughnessy MV, Read SE. Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS. The Journal of Infectious Diseases. 172: 1375-9. PMID 7594682 DOI: 10.1093/Infdis/172.5.1375 |
0.24 |
|
| 2019 |
Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, et al. Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Leukemia & Lymphoma. 1-8. PMID 30628511 DOI: 10.1080/10428194.2018.1563691 |
0.238 |
|
| 2016 |
Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leukemia & Lymphoma. 1-11. PMID 26758422 DOI: 10.3109/10428194.2015.1135431 |
0.237 |
|
| 2005 |
Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellen B, Mattes D, Kinahan P, Meyer J, Phillips M, Leblanc M, Krohn K, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head & Neck. 27: 478-87. PMID 15772953 DOI: 10.1002/Hed.20177 |
0.235 |
|
| 2019 |
Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, et al. . Blood. PMID 31331918 DOI: 10.1182/Blood.2019000719 |
0.235 |
|
| 2005 |
LeBlanc M, Moon J, Kooperberg C. Extreme regression. Biostatistics (Oxford, England). 7: 71-84. PMID 15972888 DOI: 10.1093/biostatistics/kxi041 |
0.234 |
|
| 2005 |
Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellyn B, Mattes D, Meyer J, Phillips M, Leblanc M, Kinahan P, Krohn K, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. International Journal of Radiation Oncology, Biology, Physics. 61: 129-36. PMID 15629603 DOI: 10.1016/J.Ijrobp.2004.03.040 |
0.233 |
|
| 2017 |
Blanke C, LeBlanc M, Hershman D, Ellis L, Meyskens F. Characterizing 18 Years of the Death With Dignity Act in Oregon. Jama Oncology. PMID 28384683 DOI: 10.1001/Jamaoncol.2017.0243 |
0.227 |
|
| 2019 |
Goodman PJ, Tangen CM, Darke AK, Lucia MS, Ford LG, Minasian LM, Parnes HL, LeBlanc ML, Thompson IM. Long-Term Effects of Finasteride on Prostate Cancer Mortality. The New England Journal of Medicine. 380: 393-394. PMID 30673548 DOI: 10.1056/Nejmc1809961 |
0.227 |
|
| 1997 |
Kasenda M, Calzavara LM, Johnson I, LeBlanc M. Correlates of condom use in the young adult population in Ontario Canadian Journal of Public Health-Revue Canadienne De Sante Publique. 88: 280-285. DOI: 10.17269/Cjph.88.922 |
0.226 |
|
| 1995 |
Arnold JE, Rohan T, Howe G, Leblanc M. Reproducibility and validity of a food-frequency questionnaire designed for use in girls age 7 to 12 years. Annals of Epidemiology. 5: 369-77. PMID 8653209 DOI: 10.1016/1047-2797(95)00034-5 |
0.225 |
|
| 1997 |
LeBlanc M. P01 Estimation in group sequential designs using simulated estimating equations Controlled Clinical Trials. 18. DOI: 10.1016/S0197-2456(97)91096-5 |
0.224 |
|
| 2013 |
Dey J, Dubuc AM, Pedro KD, Thirstrup D, Mecham B, Northcott PA, Wu X, Shih D, Tapscott SJ, LeBlanc M, Taylor MD, Olson JM. MyoD is a tumor suppressor gene in medulloblastoma. Cancer Research. 73: 6828-37. PMID 24092238 DOI: 10.1158/0008-5472.Can-13-0730-T |
0.223 |
|
| 2016 |
LeBlanc ML, Hershman DL, Ellis LM, Meyskens FL. Usage of Oregon's Death With Dignity Act (DWDA). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 44. PMID 28156620 DOI: 10.1200/Jco.2016.34.26_Suppl.44 |
0.222 |
|
| 2014 |
Dazard JE, Choe M, LeBlanc M, Rao JS. Cross-Validation of Survival Bump Hunting by Recursive Peeling Methods. Proceedings / American Statistical Association. American Statistical Association. Meeting. 2014: 3366-3380. PMID 26997922 |
0.219 |
|
| 2010 |
Hatton BA, Villavicencio EH, Pritchard J, LeBlanc M, Hansen S, Ulrich M, Ditzler S, Pullar B, Stroud MR, Olson JM. Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. Oncogene. 29: 3865-72. PMID 20440271 DOI: 10.1038/Onc.2010.142 |
0.219 |
|
| 2015 |
Dazard JE, Choe M, LeBlanc M, Rao JS. R package PRIMsrc: Bump Hunting by Patient Rule Induction Method for Survival, Regression and Classification. Proceedings / American Statistical Association. American Statistical Association. Meeting. 2015: 650-664. PMID 26798326 |
0.219 |
|
| 2004 |
Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 103: 4251-8. PMID 14976040 DOI: 10.1182/Blood-2003-07-2365 |
0.213 |
|
| 2003 |
Unger JM, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, Coltman CA. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 246s-252s. PMID 14645404 DOI: 10.1200/Jco.2003.08.512 |
0.213 |
|
| 2018 |
Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. The Lancet. Haematology. PMID 29396094 DOI: 10.1016/S2352-3026(18)30001-2 |
0.212 |
|
| 1994 |
Leblanc M, Tibshirani R. Adaptive Principal Surfaces Journal of the American Statistical Association. 89: 53-64. DOI: 10.1080/01621459.1994.10476445 |
0.21 |
|
| 2018 |
Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, Leonard JP, Smith SM, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg JW, Fang M. Genomic alterations important for the prognosis in patients with follicular lymphoma treated on SWOG study S0016. Blood. PMID 30446494 DOI: 10.1182/blood-2018-07-865428 |
0.201 |
|
| 2003 |
Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, ... ... LeBlanc M, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 3: 185-97. PMID 12620412 DOI: 10.1016/S1535-6108(03)00028-X |
0.2 |
|
| 2008 |
Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). Blood. 111: 4048-54. PMID 18256325 DOI: 10.1182/blood-2007-09-111708 |
0.195 |
|
| 2011 |
Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SH, LeBlanc M, Urba SG. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Investigational New Drugs. 29: 352-9. PMID 19937365 DOI: 10.1007/s10637-009-9348-z |
0.194 |
|
| 2018 |
Blanke CD, Leblanc M, Hershman D, Meyskens F, Taylor L, Ellis LM. Medical-aid-in-dying use in the US Pacific Northwest. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy295.026 |
0.191 |
|
| 2023 |
Burack WR, Li H, Adlowitz DG, Spence JM, Rimsza LM, Shadman M, Spier C, Kaminski MS, Leonard JP, Leblanc M, Smith SM, Friedberg JW. Subclonal TP53 mutation are frequent and predict resistance to radio-immunotherapy in follicular lymphoma. Blood Advances. PMID 37379264 DOI: 10.1182/bloodadvances.2022009467 |
0.19 |
|
| 2012 |
Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, Leblanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica. 97: 937-42. PMID 22271896 DOI: 10.3324/Haematol.2011.050419 |
0.19 |
|
| 2022 |
Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW. Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica. PMID 35833300 DOI: 10.3324/haematol.2022.281004 |
0.189 |
|
| 2020 |
Unger JM, Blanke CD, LeBlanc M, Hershman DL. Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. Jama Network Open. 3: e2010651. PMID 32478845 DOI: 10.1001/jamanetworkopen.2020.10651 |
0.189 |
|
| 2019 |
Unger JM, Nghiem VT, Hershman DL, Vaidya R, LeBlanc M, Blanke CD. Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. Jama Network Open. 2: e1910593. PMID 31483471 DOI: 10.1001/jamanetworkopen.2019.10593 |
0.188 |
|
| 2022 |
Unger JM, LeBlanc M, George S, Wolmark N, Curran WJ, O'Dwyer PJ, Schnall MD, Mannel RS, Mandrekar SJ, Gray RJ, Zhao F, Bah M, Vaidya R, Blanke CD. Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201826. PMID 36480773 DOI: 10.1200/JCO.22.01826 |
0.186 |
|
| 2023 |
Unger JM, Xiao H, Vaidya R, LeBlanc M, Hershman DL. Medicaid Expansion of the Patient Protection and Affordable Care Act and Participation of Patients With Medicaid in Cancer Clinical Trials. Jama Oncology. PMID 37590003 DOI: 10.1001/jamaoncol.2023.2800 |
0.185 |
|
| 2010 |
Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3330-5. PMID 20498388 DOI: 10.1200/JCO.2009.25.6834 |
0.185 |
|
| 2021 |
Unger JM, Xiao H, LeBlanc M, Hershman DL, Blanke CD. Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. Jama Network Open. 4: e2118433. PMID 34323986 DOI: 10.1001/jamanetworkopen.2021.18433 |
0.178 |
|
| 2015 |
Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, et al. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2399-404. PMID 26077240 DOI: 10.1200/JCO.2014.60.6327 |
0.178 |
|
| 2009 |
Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI. Reply to M.C. Chamberlain Journal of Clinical Oncology. 27. DOI: 10.1200/Jco.2009.22.2166 |
0.176 |
|
| 2022 |
Unger JM, Vaidya R, Albain KS, LeBlanc M, Minasian LM, Gotay CC, Henry NL, Fisch MJ, Lee SM, Blanke CD, Hershman DL. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102377. PMID 35119908 DOI: 10.1200/JCO.21.02377 |
0.176 |
|
| 2023 |
Janczewski LM, Browner A, Cotler J, Nelson H, Ballman KV, LeBlanc M, Gollub MJ, Eng C, Brierley JD, Palefsky JM, Goldberg RM, Goodman KA, Washington MK, Asare EA, Palis B. Data-driven optimization of version 9 American Joint Committee on Cancer staging system for anal cancer. Cancer. PMID 38140735 DOI: 10.1002/cncr.35155 |
0.175 |
|
| 2008 |
Swinnen LJ, LeBlanc M, Grogan TM, Gordon LI, Stiff PJ, Miller AM, Kasamon Y, Miller TP, Fisher RI. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 86: 215-22. PMID 18645482 DOI: 10.1097/Tp.0B013E3181761659 |
0.174 |
|
| 2023 |
Harris LN, Blanke CD, Erba HP, Ford JM, Gray RJ, LeBlanc ML, Hu-Lieskovan S, Litzow MR, Luger SM, Meric-Bernstam F, O'Dwyer PJ, Othus MKD, Politi K, Shepherd LE, Allegra CJ, et al. The New NCI Precision Medicine Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37531248 DOI: 10.1158/1078-0432.CCR-23-0917 |
0.174 |
|
| 2019 |
Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW. Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood. PMID 30723079 DOI: 10.1182/blood-2018-08-870915 |
0.167 |
|
| 2023 |
Unger JM, Qian L, Redman MW, Tavernier SS, Minasian L, Sigal EV, Papadimitrakopoulou VA, LeBlanc M, Cleeland CS, Dzingle SA, Summers TJ, Chao H, Madhusudhana S, Villaruz L, Crawford J, et al. Quality-of-life outcomes and risk prediction for patients randomized to Nivolumab/Ipilimumab vs Nivolumab on LungMAP-S1400I. Journal of the National Cancer Institute. PMID 36625510 DOI: 10.1093/jnci/djad003 |
0.161 |
|
| 2024 |
Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Thompson I, Agarwal N. Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer and Prostatic Diseases. PMID 38424319 DOI: 10.1038/s41391-024-00813-3 |
0.155 |
|
| 2004 |
Unger JM, LeBlanc M, Thompson IM, Coltman CA. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. Urologic Oncology. 22: 362-8. PMID 15283898 DOI: 10.1016/j.urolonc.2004.04.009 |
0.152 |
|
| 2022 |
Ramsaran E, Dai Q, Sundaresan D, Leblanc M, Amblihalli V, Muthyala A, Preusse P, Leblanc C, Li P, Andries N, Cai P, Shah N. Mortality in Stable Coronary Disease in Patients With Intermediate- or High-Risk Myocardial Perfusion Imaging. The American Journal of Cardiology. 168: 1-10. PMID 35074212 DOI: 10.1016/j.amjcard.2021.12.018 |
0.151 |
|
| 2020 |
Dai JY, Stanford JL, LeBlanc M. A multiple-testing procedure for high-dimensional mediation hypotheses. Journal of the American Statistical Association. 117: 198-213. PMID 35400115 DOI: 10.1080/01621459.2020.1765785 |
0.15 |
|
| 2020 |
Munro L, Myers G, Gould O, LeBlanc M. Clinical pharmacy services in an ambulatory oncology clinic: Patient perception and satisfaction. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 1078155220950412. PMID 32842862 DOI: 10.1177/1078155220950412 |
0.148 |
|
| 2023 |
Lara PN, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, et al. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. European Urology. PMID 37085425 DOI: 10.1016/j.eururo.2023.03.036 |
0.148 |
|
| 2014 |
Edwards SJ, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J, Laing K, Whelan MA, MacKinnon NJ. Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. Journal of Pharmacy Practice. 27: 46-52. PMID 24065784 DOI: 10.1177/0897190013504954 |
0.148 |
|
| 2006 |
Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, Unger JM, Leblanc M, Staudt LM, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood. 107: 1101-7. PMID 16239429 DOI: 10.1182/Blood-2005-04-1510 |
0.143 |
|
| 2021 |
Moon J, LeBlanc M, Othus M. Accounting for All Patients in Waterfall Plots. Jco Clinical Cancer Informatics. 5: 414-420. PMID 33830787 DOI: 10.1200/CCI.20.00150 |
0.133 |
|
| 2023 |
Adams BB, Sansom B, Doiron N, Doucette D, Gagnon J, Landry D, LeBlanc M, Levesque J, Louis F, MacLaggan T, Naylor HK. The New Brunswick Pharmacy Assessment Clinic: A Novel, Pharmacist-Led, Virtual Collaborative Practice Hub for the Assessment and Prescribing of Nirmatrelvir/Ritonavir for Patients with COVID-19. The Canadian Journal of Hospital Pharmacy. 76: 327-330. PMID 37767393 DOI: 10.4212/cjhp.3365 |
0.12 |
|
| 2023 |
Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, ... ... LeBlanc ML, et al. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). Jco Precision Oncology. 7: e2300218. PMID 37677122 DOI: 10.1200/PO.23.00218 |
0.12 |
|
| 2023 |
Unger JM, Till C, Hwang JP, Arnold KB, Leblanc M, Hershman DL, Ramsey SD. Risk Prediction of Hepatitis B or C or HIV Among Newly Diagnosed Cancer Patients. Journal of the National Cancer Institute. PMID 36946291 DOI: 10.1093/jnci/djad053 |
0.113 |
|
| 2020 |
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. The Lancet. Oncology. PMID 33125909 DOI: 10.1016/S1470-2045(20)30475-7 |
0.103 |
|
| 2022 |
Tibensky B, Hutton L, Wentzell J, LeBlanc M, Edwards S, McFarlane T. Clinical Pharmacy Services in Ambulatory Oncology: An Environmental Scan of the Canadian Practice Landscape. The Canadian Journal of Hospital Pharmacy. 75: 259-266. PMID 36246438 DOI: 10.4212/cjhp.3208 |
0.099 |
|
| 2016 |
LeBlanc M, Nawano A, Wright WJ, Gu X, Uhl JT, Dahmen KA. Avalanche statistics from data with low time resolution. Physical Review. E. 94: 052135. PMID 27967111 DOI: 10.1103/Physreve.94.052135 |
0.091 |
|
| 2018 |
Basch CH, LeBlanc M, Ethan D, Basch CE. Violence depicted in advertisements on LinkNYC kiosks in Manhattan, New York City. International Journal of Adolescent Medicine and Health. PMID 30256761 DOI: 10.1515/Ijamh-2018-0033 |
0.083 |
|
| 2019 |
Al Rabadi L, LeBlanc M, Bucy T, Ellis LM, Hershman DL, Meyskens FL, Taylor L, Blanke CD. Trends in Medical Aid in Dying in Oregon and Washington. Jama Network Open. 2: e198648. PMID 31397857 DOI: 10.1001/jamanetworkopen.2019.8648 |
0.081 |
|
| 2013 |
LeBlanc M, Angheluta L, Dahmen K, Goldenfeld N. Universal fluctuations and extreme statistics of avalanches near the depinning transition. Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics. 87: 022126. PMID 23496478 DOI: 10.1103/Physreve.87.022126 |
0.074 |
|
| 2023 |
Alunni A, Pierre C, Torres-Paz J, Clairet N, Langlumé A, Pavie M, Escoffier-Pirouelle T, Leblanc M, Blin M, Rétaux S. An Astyanax mexicanus mao knockout line uncovers the developmental roles of monoamine homeostasis in fish brain. Development, Growth & Differentiation. PMID 37843474 DOI: 10.1111/dgd.12896 |
0.066 |
|
| 2016 |
Basch CH, Fullwood MD, LeBlanc M. Violence in Advertisements in New York City Subway Stations: A Pilot Study. Journal of Community Health. 41: 387-91. PMID 26518776 DOI: 10.1007/s10900-015-0108-z |
0.066 |
|
| 2015 |
Brinkman BA, LeBlanc M, Ben-Zion Y, Uhl JT, Dahmen KA. Probing failure susceptibilities of earthquake faults using small-quake tidal correlations. Nature Communications. 6: 6157. PMID 25625338 DOI: 10.1038/Ncomms7157 |
0.063 |
|
| 2016 |
Mitchell F, Gould O, LeBlanc M, Manuel L. Opinions of Hospital Pharmacists in Canada Regarding Marijuana for Medical Purposes. The Canadian Journal of Hospital Pharmacy. 69: 122-30. PMID 27168633 DOI: 10.4212/Cjhp.V69I2.1539 |
0.058 |
|
| 2012 |
LeBlanc M, Angheluta L, Dahmen K, Goldenfeld N. Distribution of maximum velocities in avalanches near the depinning transition. Physical Review Letters. 109: 105702. PMID 23005300 DOI: 10.1103/Physrevlett.109.105702 |
0.057 |
|
| 2014 |
Antonaglia J, Wright WJ, Gu X, Byer RR, Hufnagel TC, LeBlanc M, Uhl JT, Dahmen KA. Bulk metallic glasses deform via slip avalanches. Physical Review Letters. 112: 155501. PMID 24785049 DOI: 10.1103/Physrevlett.112.155501 |
0.051 |
|
| 2019 |
Gallagher A, Gould O, LeBlanc M, Manuel L, Brideau-Laughlin D. Knowledge and Attitudes of Hospital Pharmacy Staff in Canada Regarding Medical Assistance in Dying (MAiD). The Canadian Journal of Hospital Pharmacy. 72: 16-26. PMID 30828090 |
0.048 |
|
| 2018 |
Basch CH, Ethan D, LeBlanc M, Basch CE. A Description of Advertisements for Alcohol on LinkNYC Kiosks in Manhattan, New York City: A Pilot Study. Journal of Community Health. PMID 29484514 DOI: 10.1007/S10900-018-0485-1 |
0.046 |
|
| 2015 |
Carroll R, Lee C, Tsai CW, Yeh JW, Antonaglia J, Brinkman BA, LeBlanc M, Xie X, Chen S, Liaw PK, Dahmen KA. Experiments and Model for Serration Statistics in Low-Entropy, Medium-Entropy, and High-Entropy Alloys. Scientific Reports. 5: 16997. PMID 26593056 DOI: 10.1038/Srep16997 |
0.045 |
|
| 2015 |
Uhl JT, Pathak S, Schorlemmer D, Liu X, Swindeman R, Brinkman BA, LeBlanc M, Tsekenis G, Friedman N, Behringer R, Denisov D, Schall P, Gu X, Wright WJ, Hufnagel T, et al. Universal Quake Statistics: From Compressed Nanocrystals to Earthquakes. Scientific Reports. 5: 16493. PMID 26572103 DOI: 10.1038/Srep16493 |
0.045 |
|
| 2016 |
Fullwood MD, Basch CH, LeBlanc M. Implications for visually stimulating advertisements on NYC subway platforms. International Journal of Adolescent Medicine and Health. PMID 26974129 DOI: 10.1515/ijamh-2015-0112 |
0.041 |
|
| 2010 |
Hansen PA, LeBlanc M, Cook NB, Williams K. The quality of post and cores made using a reduce-time casting technique. Operative Dentistry. 34: 709-15. PMID 19953781 DOI: 10.2341/08-122-L |
0.039 |
|
| 2008 |
Hamm E, Reis P, LeBlanc M, Roman B, Cerda E. Tearing as a test for mechanical characterization of thin adhesive films. Nature Materials. 7: 386-90. PMID 18376397 DOI: 10.1038/nmat2161 |
0.019 |
|
| 2020 |
Persky DO, Smith SM, LeBlanc ML, Friedberg JW. Reply to E. Hawkes et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002856. PMID 33104437 DOI: 10.1200/JCO.20.02856 |
0.019 |
|
| Hide low-probability matches. |